Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

Eli Lilly and Co. is shelling out $1 billion to buy a Boston biotech known for genetic medicines for cardiovascular disease.

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond ...

Verve Therapeutics’ stock rallies by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly & Co. agreed to buy Verve Therapeutics Inc., a US biotech that’s seeking to use gene editing to prevent clogged arteries, for as much as $1.3 billion.

Indianapolis: Eli Lilly and Company and Verve Therapeutics have announced a definitive agreement for Lilly to acquire Verve ...

Slope, a biospecimen lifecycle software company, and the Biospecimen Management Consortium (BMC), a clinical trial ...

The clearer the lakes, the greater the property values around them, Lilly Center for Lakes & Streams Director Dr. Nate Bosch ...